EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Research Progress on Varicella-Zoster Virus Vaccines

Hongjing Liu, Lingyan Cui, Sibo Zhang, Hong Wang, Wenhui Xue, Hai Li, Yuyun Zhang, Lin Chen, Ying Gu iD, Tingting Li iD, Ningshao Xia iD, Shaowei Li iD

Vaccines · 04.07.2025 · 13 (7) · 730

DOI: 10.3390/vaccines13070730 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 04.07.2025. Verfasst von Hongjing Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, School of Life Sciences, Xiamen U…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program, the Fundamental Research Funds for the Central Universities, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Varicella-zoster virus (VZV) poses significant public health challenges as the etiological agent of varicella (chickenpox) and herpes zoster (HZ), given its high transmissibility and potential for severe complications. The introduction of VZV vaccines—particularly the vOka-based live attenuated and glycoprotein gE-based recombinant subunit vaccines—has substantially reduced the global incidence of these diseases. However, live attenuated vaccines raise concerns regarding safety and immunogenicity, especially in immunocompromised populations, while recombinant subunit vaccines, such as Shingrix, exhibit high efficacy but are associated with side effects and adjuvant limitations. Recent advancements in vaccine technology, including mRNA vaccines, viral vector vaccines, and virus-like particle (VLP) vaccines, offer promising alternatives with improved safety profiles and durable immunity. This review synthesizes current knowledge on VZV vaccine mechanisms, clinical applications, and immunization strategies, while also examining future directions in vaccine development. The findings underscore the pivotal role of VZV vaccines in disease prevention and highlight the need for continued research to enhance their public health impact.

Schlagwörter

Stichwörter der Autor:innen

cell-mediated immunityherpes zostervaccine platformsvaccinesvaricellavaricella-zoster virus

Autor:innen und Institutionen

  • State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, School of Life Sciences, Xiamen University, Xiamen 361102, China.
  • National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Collaborative Innovation Center of Biologic Products, National I…

ORCID-Profile: Ying Gu, Tingting Li, Ningshao Xia, Shaowei Li

Förderung

  • the National Key Research and Development Program
  • the Fundamental Research Funds for the Central Universities
  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Liu, H., Cui, L., Zhang, S., Wang, H., Xue, W., Li, H., Zhang, Y., Chen, L., Gu, Y., Li, T., Xia, N., & Li, S. (2025). Research Progress on Varicella-Zoster Virus Vaccines. Vaccines, 13(7), 730. https://doi.org/10.3390/vaccines13070730

Vancouver

Liu H, Cui L, Zhang S, Wang H, Xue W, Li H, et al. Research Progress on Varicella-Zoster Virus Vaccines. Vaccines. 2025;13(7):730. doi:10.3390/vaccines13070730

BibTeX
@article{Liu2025,
  author = {Liu, Hongjing and Cui, Lingyan and Zhang, Sibo and Wang, Hong and Xue, Wenhui and Li, Hai and Zhang, Yuyun and Chen, Lin and Gu, Ying and Li, Tingting and Xia, Ningshao and Li, Shaowei},
  title = {Research Progress on Varicella-Zoster Virus Vaccines},
  journal = {Vaccines},
  year = {2025},
  volume = {13},
  number = {7},
  pages = {730},
  doi = {10.3390/vaccines13070730}
}
Kostenlos starten →